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affecting the physician prescribing decision included safety (96%),
efﬁcacy (90%), and cost (86%) of drug choice while the patients
viewed that efﬁcacy (86%), convenient dosage (53%), and safety
(42%) of a drug were their main concerns. About eight out of ten
patients reported that the sources of information for pain man-
agement were from specialists, friends/family, GPs and TV/Radio.
Nevertheless, most patients were not proactively discussing the
potential risks associated with prescription of NSAIDs with their
doctors. CONCLUSIONS: Different concerns and information
communicated by doctors may affect how it is perceived by
patients. Effective patient education is essential to encourage a
two-way communication between physician-patient to minimize
the negative outcomes and maximize the quality of care.
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OBJECTIVES: Health-related quality of life (HRQL) and its
impact upon productivity have not been well documented among
hemophilia patients, nor among their caregivers. This study of
hemophilia patients with inhibitors assessed patient and family
caregiver productivity and the impact of patient HRQL.
METHODS: Inhibitor patients who participated in a patient
forum were mailed a survey including questions on clinical and
demographic characteristics, aspects of medical care, HRQL (via
the SF-12 v2), and productivity. 53 of 90 surveys were returned.
Regression analyses assessed the association of patient and treat-
ment factors with HRQL mean physical (PCS) and mental (MCS)
composite summary scores and patient and caregiver productivity
(missed and low productivity days in the past year). RESULTS:
Patient mean age was 20.7 years (SD = 18.8), 88.5% were type A,
and 39.6% received on-demand therapy as their only treatment
mode. On-demand treatment (B = -0.336, P < 0.05) and number
of hemorrhages (B = -0.366, P < 0.05) were negatively associated
with PCS; and PCS was associated with patients’ missed work/
school days (IRR = 0.93, P < 0.001) and perceived impact on
daily activities (OR = 0.72, P < 0.05). PCS (IRR = 0.94, P < 0.01),
hemorrhages (IRR = 1.05, P < 0.05), surgery (IRR = 2.74,
P < 0.05), and younger age (IRR = 0.91, P < 0.01)were associated
with patients’ low productivity days. Patient surgery was associ-
ated with more caregiver missed days (IRR = 3.70, P < 0.05) and
more caregiver low productivity days (IRR = 8.99, P < 0.001).
Patient MCS was also associated with caregiver low productivity
days (IRR = 0.96, P < 0.01). CONCLUSIONS: Physical aspects
of HRQL among hemophilia patients with inhibitors impact their
daily activities and productivity; mental aspects of HRQL affected
the productivity of family caregivers.
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OBJECTIVES: Using the French national database of hospital
admissions in 2006, we estimated the economic burden for hos-
pitals of immune thrombocytopenic purpura (ITP) and ITP-
related splenectomy. METHODS: In France, public and private
hospital admissions are recorded in comprehensive administra-
tive databases that generate Diagnosis Related Groups (DRGs)
used for billing purposes, ICD10 diagnosis, and procedures
codes. Admissions for ITP were extracted. Admissions for ITP-
related splenectomy were identiﬁed by analyzing the surgical
procedures. Linking of each hospital stay and patient was made
to estimate the cost of ITP per patient. Admission costs from the
health care perspective were estimated from the 2007 ofﬁcial
DRG tariffs. RESULTS: In 2006, 10 561 hospital admissions for
ITP were recorded, of which 10,047 (95%) were in public or not
for proﬁt hospitals. In the public sector, 37 hospitals (i.e. 10% of
all public health care facilities) managed 50% of the caseload.
There were 269 admissions for ITP-related splenectomy, mainly
in the public sector (91%). Altogether 3612 patients in the public
sector required 9360 admissions or 2.80 in-patient admissions
per patient per year. In the private sector, 150 patients required
508 stays (3.4 hospital stays/patient/year). Based on these results,
the mean charge was €3653 per patient in public hospitals, and
€3177 per patient in private hospitals. The mean charge per
patient in public hospitals for ITP-related splenectomy was
€6367. These costs did not include expensive drugs, in particular
immunoglobulins or rituximab, which are excluded from the
DRGs reimbursement scheme in France and can result in extra
billing. CONCLUSIONS: Administrative databases allow the
estimation of the burden of ITP for hospitals. ITP and ITP-
related splenectomy were managed mostly in the public sector.
Splenectomy increased the cost per patient twofold. The cost of
expensive drugs to treat ITP must be evaluated in a separate
study.
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OBJECTIVES: Prior literature has suggested that the B domain
of FVIII may play a role in the rate of FVIII inactivation (Krenov
2006). Faster inactivation of recombinant B domain-deleted
factor VIII (BDD-rFVIII) could affect efﬁcacy during prophy-
laxis, potentially leading to increased risk for breakthrough
bleeds and higher FVIII utilization. The objective of this analysis
was to use real world data to determine whether patients treated
with BDD-rFVIII had higher annual FVIII utilization than
matched patients treated with full-length rFVIII (FL-rFVIII).
METHODS: Retrospective analysis of a large, US specialty phar-
macy database was conducted using 2006/2007 data. Patients
who were not receiving Immune Tolerance Therapy, had at least
six months of prescription activity, and did not switch brands
or treatment regimens were selected. BDD-rFVIII patients were
matched with up to 5 FL-rFVIII patients based on treatment
regimen (on-demand and prophylaxis), hemophilia severity and
age. The annualized number of international units (IU) dispensed
per kilogram was compared between both rFVIII groups using a
Wilcoxon Matched Pairs Test. Subgroup analysis was performed
by treatment regimen. RESULTS: Twenty-two BDD-rFVIII
patients met the inclusion criteria and were matched to 104
FL-rFVIII patients. Median annual IU/kg consumed for all BDD-
rFVIII and FL-rFVIII patients was 3630 and 3054 respectively
(p = 0.20). Subgroup analysis showed a statistically signiﬁcant
difference observed when comparing patients on a prophylactic
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